Guillaume Köszegi’s Post

Be a Catalyst for Change! 🚀 Your insights on aptamer-based therapeutics for challenging cancer biomarkers can shape the future of medicine. Join our survey and make a lasting impact! 💪 #MedicalInnovation #CancerResearch #Survey https://lnkd.in/e_dvXpSN

Thanks Drug Target Review for delving into our lead drug candidate with the potential for broad cancer killing. In this interview, I discuss the challenges posed by heterogenous and treatment-resistant tumors in cancer treatments. To achieve durable tumor responses, a cancer drug must offer potent tumor cytotoxicity, preserve nearby immune cells and healthy tissue, and avoid resistance mechanisms. We believe N17350 has all three of these attributes and we are looking forward to our clinical trials this year in skin cancers, head and neck cancer, and triple-negative breast cancer.

2 more days left at the #AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference at the Hynes Convention Center in Boston, MA (Sat 10/14 last day). Drop by and visit intoDNA at booth 503 to learn more about STRIDE for direct SSB and DSB visualization, quantification and analysis in-situ for cell lines, tissues, PBMCs and more. If you are a gH2AX user for indirectly assessing DNA damage we encourage you to learn more about our direct STRIDE technology to compare and validate your results. We can run both assays together on the same samples. #cancer #therapy #ddr #dna #stride #technology #biotech

Is biomarker testing part of personalized/precision medicine? Find out more in our latest interview with expert Jialu Liu from Frontage Laboratories, Inc, as he explains the major challenges of biomarkers in cancer drug discovery and development. https://bit.ly/45bZ4gL

...and now we are going to defeat cancer. 1️⃣ Small molecule oral cancer drug kills 100% of 70 types of solid tumors in vitro and in animal models 2️⃣ therapeutic index of 6 3️⃣ no discernible side effects 4️⃣ Phase 1 trials now underway https://lnkd.in/dq3XrVpV AI is making all the difference. #acceleration #humanevolution #evolution #cancerresearch #tumors #cancertreatment #artificialintelligence

#Availableforlicense: New pathways for biomarkers and drug discovery for cancer patients. This technology defines ABI1-AR reciprocal regulation involving two non-exclusive molecular mechanisms of ABI1-AR and ABI1-DNA interactions. Benefits include: ✅ Provides a novel mechanism for predicting survival rates among cancer patients. ✅ May enable drug discovery for a wide variety of cancers. Get all the details here: https://lnkd.in/gthFAsfu or reach out to our Business Development and Licensing Professional Andrew Scheinman at [email protected] to partner with us today! #SUNYTech #SUNYInnovation #SUNYImpact

We are excited about positive overall survival results in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype in our Ph2 trial of investigational BXCL701. Learn more. https://bit.ly/3Qsa30c

September is #ProstateCancerAwarenessMonth and #OvarianCancerAwarenessMonth 🌟 Biomarkers like PSA, AR, MUC1, CLU, and TROP2 play a pivotal role in diagnosis and therapeutic development. Emerging biomarkers like CLU, CCNE1, and PARP open new doors for discovery. At Sino Biological, we're committed to empowering researchers with rigorously validated antibodies to make breakthroughs in cancer diagnostics and treatments. Learn more: https://ow.ly/O0A750PIRSR #CancerResearch #Bioreagents #HealthcareInnovation

Join IQVIA HCP Space https://bit.ly/3THever to learn about the role of exosomal circRNAs as potent cancer biomarkers. High sensitivity and specificity indicate a promising avenue for future clinical tests. #CancerDiagnosis #MedicalResearch

Using the biocrates life sciences ag MxP® Quant 500 kit and the Waters Corporation Xevo TQ-XS tandem quadrupole MS system, Hishinuma et al illustrated that specific metabolic profiles reflected the pathogenesis of Endometrial cancer. Further these profiles correlated well with the risk of recurrence and disease stage providing for a potential basis of diagnosis as well as an effective monitor of response to therapy. The paper is Open Access and is available through this link; https://lnkd.in/gz8UGWCd #MS4BetterCare #personalizedmedicine #metabolomics #cancerresearch